^
    1m
    An exploratory clinical study evaluating the safety, tolerability, and efficacy of the combination of purinostat mesylate, sintilimab, and apatinib in the treatment of advanced/metastatic gastric cancer (ChiCTR2500109741)
    P1, N=18, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P1 trial
    |
    HER-2 positive
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • purinostat
    2ms
    Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting --> Active, not recruiting | N=120 --> 74 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    purinostat
    3ms
    A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=390, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xpovio (selinexor) • purinostat
    5ms
    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma. (PubMed, Signal Transduct Target Ther)
    Purinostat mesylate (PM), a highly selective HDAC I/II binhibitor, exhibits excellent antitumor activity in MM and lymphoma cell lines and mouse models, outperforming the pan-HDAC inhibitor panobinostat or first-line/second-line multi-drug combinations. Additionally, PM combined with pomalidomide and dexamethasone showed strong synergistic activity in r/r MM treatment. These findings support further open-label, multicenter phase Ib/IIa trials of PM combination therapy with immunomodulators for r/r MM, as well as phase II monotherapy trials for r/r DLBCL and r/r T-cell lymphoma.
    P1 data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    pomalidomide • Farydak (panobinostat) • purinostat
    6ms
    A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P3 trial
    |
    Xpovio (selinexor) • purinostat
    6ms
    An open, multicenter Phase Ib/IIa study to evaluate the safety, tolerability, pharmacokinetics, and initial efficacy of combination purinostat mesylate for injection in advanced solid tumors (ChiCTR2500101668)
    P=N/A, N=132, Recruiting, Sun Yat-sen Memorial Hospital,Sun Yat-sen University/West China Hospital of Sichuan University; Chengdu Zenitar Biomedical Technology Co., Ltd.
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • HER-2 positive • BRAF V600E • ER positive • EGFR mutation • TMB-H • MSI-H/dMMR • HER-2 negative • BRAF V600 • HER-2 expression • HER-2 underexpression • FGFR2 mutation
    |
    Tevimbra (tislelizumab-jsgr) • fulvestrant • purinostat
    8ms
    A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Initiation date: Nov 2023 --> Apr 2024
    Trial initiation date
    |
    purinostat
    8ms
    Phase II clinical study of purinostat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (ChiCTR2500098231)
    P2, N=120, Completed, West China Hospital of Sichuan University/Ruijin Hospital of Shanghai Jiao Tong University School of Medicine; Chengdu Zenitar Biomedical Technology C
    New P2 trial
    |
    purinostat
    8ms
    Phase Ib/IIa clinical study of purinostat mesylate for injection in combination with To determine the maximum tolerated dose (MTD) and phase IIa recommended dose (RP2D) of pomalidomide mesylate for injection in combination with fixed-dose pomalidomide capsules and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). capsule and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (ChiCTR2500098210)
    P1/2, N=123, Recruiting, West China Hospital of Sichuan University/Peking University People's Hospital; Chengdu Zenitar Biomedical Technology Co., Ltd.
    New P1/2 trial
    |
    pomalidomide • purinostat
    8ms
    Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Initiation date: Jun 2024 --> Mar 2024
    Trial initiation date
    |
    pomalidomide • purinostat
    9ms
    A Clinical Study of Purinostat Mesylate for Injection in Patients with Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • exemestane • purinostat
    9ms
    Purinostat Mesylate Combined with Pomalidomide Capsules and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide • purinostat